# Assessment of lixisenatide-induced nephropathy in chick embryos: Implications for prevention of diabetic kidney disease

## TL;DR

This study shows that lixisenatide protects kidneys in a chick embryo model of diabetes, even without improving overall metabolism.

## Contribution

The paper demonstrates lixisenatide's direct nephroprotective effects independent of systemic metabolic control.

## Key findings

- Hyperglycemia caused kidney damage in chick embryos, including oxidative stress and inflammation.
- Lixisenatide reduced kidney injury markers like MDA, TNF-α, and caspase-3 activity at high doses.
- The drug normalized kidney-to-body ratios and preserved renal structure in hyperglycemic embryos.

## Abstract

Diabetic kidney disease (DKD) is a major cause of end-stage renal disease and the direct renal effects of GLP-1 receptor agonists
remain underexplored. Using a hyperglycemic chick embryo model (n=120), we evaluated dose-dependent nephroprotective effects of
lixisenatide. Hyperglycemia induced renal hypertrophy, histological injury, oxidative stress, inflammation and apoptosis. Lixisenatide,
particularly at high doses, significantly ameliorated these changes, normalizing kidney-to-body ratios and reducing MDA, TNF-α and
caspase-3 activity. Thus, we show that lixisenatide directly preserves renal structure and function independent of systemic metabolic
control.